Skip to main content
SpringerLink
Log in
Book cover

Multidisciplinary Management of Rectal Cancer pp 355–358Cite as

“Are There New Chemotherapy Drugs Behind the Corner?”

  • Chapter
  • First Online:

  • 966 Accesses

Abstract

Up to now, the backbone of both adjuvant and palliative chemotherapy for colorectal cancer is still represented by 5-fluorouracil (5FU). However, we have currently several approved drugs with significant clinical activity in metastatic colon cancer. Apart from cytotoxics such as oxaliplatin, irinotecan, and fluoropyrimidines, we have antiangiogenics (bevacizumab, aflibercept, and ramucirumab), anti-epidermal growth factor receptor (EGFR), and tyrosine kinase inhibitors such as regorafenib. Despite remarkable prolongation of median survival, exceeding 24 months, most patients will be progressing over different lines of therapy, and there is a need and a role for new compounds to be added to our therapeutic armamentarium to improve efficacy [1].

This is a preview of subscription content, log in via an institution.

References

  1. Van Cutsem E, Cervantes A, Nordlinger B et al (2014) Metastatic colorectal cancer ESMO guideline. Ann Oncol 25(suppl 3):iii1–iii9

    Article  PubMed  Google Scholar 

  2. Tanaka N, Sakamoto K, Okabe H et al (2014) Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 32:2319–2326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909–1919

    Article  PubMed  Google Scholar 

  4. Koefoed K, Steinaa L, Søderberg JN, Kjær I, Jacobsen HJ, Meijer PJ et al (2011) Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 3:584–595

    Article  PubMed  PubMed Central  Google Scholar 

  5. Dienstmann R, Patnaik A, Garcia-Carbonero R et al (2015) Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov 5:598–609

    Article  CAS  PubMed  Google Scholar 

  6. Ciardiello F, Normanno N (2011) HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. Cancer Discov 1:472–474

    Article  CAS  PubMed  Google Scholar 

  7. Siena S, Sartore-Bianchi A, Lonardi S et al (2015) Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial. Presented at 2015 ASCO annual meeting. J Clin Oncol 33(suppl; abstr 3508)

    Google Scholar 

  8. The Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337

    Article  PubMed Central  Google Scholar 

  9. Guinney J, Dienstmann R, Wang X et al (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21:1350–1356

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Taube JM, Klein A, Brahmer JR et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064–5074

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Avenida Menéndez y Pelayo 4, Valencia, 46010, Spain

    Valentina Gambardella, Noelia Tarazona, Marisol Huerta & Andres Cervantes

Authors
  1. Valentina Gambardella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noelia Tarazona
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marisol Huerta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andres Cervantes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andres Cervantes .

Editor information

Editors and Affiliations

  1. Dept. of Radiation Oncology, Università Cattolica S Cuore, Rome, Italy

    Vincenzo Valentini

  2. Head, Div. Clinical Oncology Research, University Clinic Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Sachsen-Anhalt, Germany

    Hans-Joachim Schmoll

  3. Department of Surgery, Leiden Univ Med Ctr, Leiden, The Netherlands

    Cornelis J. H. van de Velde

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag Berlin Heidelberg

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gambardella, V., Tarazona, N., Huerta, M., Cervantes, A. (2018). “Are There New Chemotherapy Drugs Behind the Corner?”. In: Valentini, V., Schmoll, HJ., van de Velde, C. (eds) Multidisciplinary Management of Rectal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-43217-5_45

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43217-5_45

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43215-1

  • Online ISBN: 978-3-319-43217-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation